Fate Therapeutics (FATE) vs Zura Bio (ZURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Fate Therapeutics (FATE) has outperformed Zura Bio (ZURA) over the past year, losing 10.8% versus a loss of 74.4%. Fate Therapeutics is the larger company by market cap ($111.8 million vs $89.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FATE | ZURA |
|---|---|---|
| Share price | $0.919 | $0.9305 |
| Market cap | $111.82M | $89.63M |
| 1-day change | -9.01% | -2.30% |
| YTD return | -6.22% | -82.24% |
| 1-year return | -10.78% | -74.37% |
| 5-year return | -98.25% | — |
| EPS (TTM) | $-1.03 | $-1.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $6.65M | — |
| Revenue growth (YoY) | -51.24% | — |
| Net income (latest FY) | $-136.31M | $-68.65M |
| Operating margin | -2222.45% | — |
| Net margin | -2051.08% | — |
| 52-week high | $3.23 | $7.44 |
| 52-week low | $0.90 | $0.919 |
| Distance from 52-week high | -71.55% | -87.49% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +522.42% | +759.75% |
| Average volume | 1.53M | 4.47M |
| Shares outstanding | 121.67M | 96.33M |
| Employees | 161 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FATE has outperformed ZURA by 63.6 percentage points over the past year.
About Fate Therapeutics
FATE stock →Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 161 employees
About Zura Bio
ZURA stock →Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 40 employees
FATE vs ZURA FAQ
Which is bigger, Fate Therapeutics or Zura Bio?
Fate Therapeutics (FATE) is larger, with a market capitalization of $111.82M compared with $89.63M for Zura Bio (ZURA).
Which stock has performed better over the past year, FATE or ZURA?
FATE returned -10.78% over the past 12 months, compared with -74.37% for ZURA (price return, excluding dividends). Past performance does not predict future results.
Are Fate Therapeutics and Zura Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.